HPLC-CAD impurity profiling of carbocisteine using SCX-RP mixed-mode chromatography

Significance of the Topic

Carbocisteine is a non-proteinogenic amino acid widely prescribed as a mucolytic agent in acute and chronic respiratory diseases. Reliable impurity profiling is critical for drug safety, as regulatory guidelines (ICH Q3A) mandate reporting thresholds of 0.03% (m/m) for individual impurities. Traditional derivatization methods (ninhydrin, OPA) can miss non-reactive impurities, underscoring the need for direct detection approaches.

Objectives and Study Overview

This work adapts and modernizes an existing HPLC method by integrating a Thermo Scientific Vanquish Charged Aerosol Detector (CAD) with strong cation exchange–reversed-phase (SCX-RP) mixed-mode chromatography. The goal was to lower limits of quantitation (LOQs) for carbocisteine impurities, particularly cystine, to meet or exceed the 0.03% regulatory threshold.

Methodology and Instrumentation

The optimized method employed:

• Column: SIELC Primesep 100 (250 × 4.6 mm, 5 μm) offering combined hydrophobic and cation-exchange retention.
• Mobile phase: 18% acetonitrile/82% water (v/v) with 10 mM trifluoroacetic acid (TFA), isocratic at 1.3 mL/min, 20 °C.
• Detector: Vanquish CAD with evaporation temperature 50 °C, filter 10 s, data rate 10 Hz.
• Sample preparation: Fresh aqueous stock solutions of carbocisteine impurities (0.05–0.25% assay concentration) with 3% ammonia added for cystine solubility; autosampler at 8 °C.

Results and Discussion

The isocratic run achieved baseline separation of carbocisteine lactam, sulfoxide diastereomers, N,S-dicarboxymethyl cysteine, tyrosine, and cystine within 20 minutes. Calibration curves (0.05–0.25% levels) showed R² > 0.995 for all impurities. LOQs on the Vanquish CAD ranged from 0.01% to 0.02%, representing an average 44% reduction compared to the older Corona CAD method; cystine LOQ improved from 0.09% to 0.01%. Precision (intra- and interday RSD <10%) and accuracy (recoveries 91–119%) met validation criteria. Analysis of eleven commercial batches revealed low-level cystine in all samples, including those previously reported as non-detectable.

Benefits and Practical Applications

• Enhanced sensitivity meets ICH reporting thresholds for all impurities.
• Direct detection of semi- and non-volatile compounds without derivatization.
• Robust, isocratic method suitable for routine quality control and impurity profiling in pharmaceutical development.

Future Trends and Opportunities

The integration of CAD with mixed-mode columns paves the way for broader application in amino acid and polar drug analysis. Future developments may include automated high-throughput workflows, coupling CAD with orthogonal detectors (e.g., mass spectrometry), and expanding the approach to other non-chromophoric pharmaceutical impurities.

Conclusion

The modernized UHPLC-CAD method on the Vanquish platform delivers superior sensitivity, precision, and robustness for carbocisteine impurity profiling. It fully satisfies regulatory requirements and enhances the reliability of low-level impurity quantification.

References

1. Zheng J-P, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371(9629):2013–2018.
2. Wahl O, Holzgrabe U. Amino acid analysis for pharmacopoeial purposes. Talanta. 2016;154:150–163.
3. ICH Q3A(R2). Impurities in New Drug Substances. ICH, CPMP/ICH/142/95; October 2006. Published in US Federal Register June 2008.
4. Wahl O, Holzgrabe U. Impurity profiling of carbocisteine by HPLC-CAD, qNMR, and UV/vis spectroscopy. J Pharm Biomed Anal. 2014;95:1–10.
5. Swartz M, Emanuele M, Awad A. Charged aerosol detection in pharmaceutical analysis. In: Gamache PH, editor. Charged Aerosol Detection for Liquid Chromatography and Related Separation Techniques. John Wiley & Sons; 2017. doi:10.1002/9781119390725.ch10.